Cédric Rossi

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Laëtitia Vercellino, Roberta Di Blasi, Salim Kanoun et al. · Blood Advances · 2020 · 387 citations · Full text

Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma

Salim Kanoun, Cédric Rossi, Alina Berriolo-Riedinger et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2014 · 175 citations

Tumor Biology, Lymphoid Neoplasia, Hodgkin Lymphoma +8

Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with <scp>non‐Hodgkin</scp> lymphoma treated with B‐cell depleting immunotherapy

Rémy Duléry, Sylvain Lamure, Marc Delord et al. · American Journal of Hematology · 2021 · 156 citations · Full text

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial

Steven Le Gouill, Franck Morschhauser, David Chiron et al. · Blood · 2020 · 127 citations · Full text

Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers

Cédric Rossi, Julia Gilhodes, Marie Maerevoet et al. · American Journal of Hematology · 2018 · 116 citations · Full text